Sitryx
PrivateLast Round
Series A
Extension
Sep 27, 2023
Total Funding Raised
$79M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sitryx operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Series A Extension round in September 2023.
Sitryx is a biopharmaceutical company that develops disease-modifying therapeutics in immuno-oncology and immuno-inflammation by regulating cell metabolism.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sitryx Comparables
Compare Sitryx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| META Pharmaceuticals Inc. | 83% | |
| Lmito Therapeutics | 83% | |
| Ventus Therapeutics | 81% |
For institutional investors. Book with your work email.
Sitryx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 27, 2023 | ||||
| Corporate Funding | Mar 31, 2020 | ||||
| Series A | Oct 8, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sitryx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series A Extension, Series A, Seed |
| Oxford Science Enterprises | Series A Extension |
| Oxford Science Enterprises | Series A Extension |
| Sofinnova Partners | Series A Extension, Series A |
| Longwood Fund | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 80% MoM, reaching 5.5K.
- Apr 2, 2026
Lead glutaminase-1 (GLS1) inhibitor nominated for development.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardOct 23, 2026
Sitryx receives the Best Established Biotech Company Award, sponsored by Precision for Medicine, at the 2026 BioUK Awards in the United Kingdom on Oct 21st '26 for pioneering immunometabolism to restore immune balance and deliver lasting remission for patients with chronic autoimmune and inflammatory disease.
For institutional investors. Book with your work email.
Sitryx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sitryx's valuation, stock price, and market status.
Is Sitryx a public or private company?
Sitryx is a private company.
What is the current stock price of Sitryx?
Sitryx is a private company, so its shares have no public market price. Caplight tracks Sitryx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sitryx worth (valuation)?
Valuation information for Sitryx is not publicly available.
Can I buy Sitryx stock?
Sitryx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sitryx's last funding round?
Sitryx's most recent funding round was Series A Extension on September 27, 2023.
Who are the main investors in Sitryx?
Key investors in Sitryx include SV Health Investors, Oxford Science Enterprises, Oxford Science Enterprises, Sofinnova Partners.
Will Sitryx IPO soon?
No public IPO plans have been announced for Sitryx.
How can I track Sitryx secondary market activity?
Caplight tracks bids, offers, and trades in Sitryx's shares on secondary markets.